Aptamer Group plc, a developer of synthetic oligonucleotide-based binding reagents for life sciences applications, and ...

Synthetic binders developer Aptamer Group has signed a licensing agreement with Alphazyme for the use of an Optimer binder in ...

Senescent “zombie” cells are linked to aging and multiple diseases, but spotting them in living tissue has been notoriously ...

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market ...

York-based biotech firm Aptamer Group has announced a licensing agreement with synthetic biology and genomics company Twist ...

Binders will establish cell types and delivery vehicles may increase uptake of the siRNA therapy Binders will establish cell types and delivery vehicles may increase uptake of the siRNA therapy ...

Aptamer Group, the developer of diagnostic and therapeutic Optimer™ reagents, today announced a commercial partnership with Mologic, a leading developer and manufacturer of lateral flow and rapid ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...

This schematic shows the secondary structure of two aptamers. The complex shapes formed by base pairing (black lines connecting G-C and A-T bases) allow aptamers to bind their targets with high ...

York-headquartered life sciences company Aptamer Group has raised £2m through a placing that will support the commercialisation of its technology as well as further R&D. The listed business has ...